Evidence map›Paper›PMID 36925803›Full record

ArticleFrontiers in health services2022

Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease.

J S Hankins, M B Potter, M E Fernandez, C Melvin, L DiMartino, S R Jacobs, H B Bosworth, A A King, J Simon, J A Glassberg and 6 more

Open access · diamondFull text read
In one paragraph

Article in Frontiers in health services, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

J S HankinsDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN, United States.
M B PotterDepartment of Family and Community Medicine, University of California San Francisco School of Medicine, San Francisco, CA, United States.
M E FernandezHealth Promotion and Behavioral Sciences, University of Texas Health Science Center, School of Public Health at Houston, Houston, TX, United States.
C MelvinThe Medical University of South Carolina, Charleston, SC, United States.
L DiMartinoRTI International, Research triangle park, NC, United States.
S R JacobsRTI International, Research triangle park, NC, United States.
H B BosworthDepartment of Population Health Studies, Duke University, Durham, NC, United States.
A A KingDepartment of Pediatrics, Washington University, Saint louis, MO, United States.
J SimonDepartment of Emergency Medicine, Ichan School of Medicine at Mount Sinai, New York, NY, United States.
J A GlassbergDepartment of Emergency Medicine, Ichan School of Medicine at Mount Sinai, New York, NY, United States.
A KutlarAugusta University, Augusta, GA, United States.
V R GordeukDepartment of Medicine, the University of Illinois at Chicago, Chicago, IL, United States.
N ShahDepartment of Pediatric Hematology and Oncology, Duke University, Durham, NC, United States.
A A BaumannDivision of Public Health Sciences, Department of Surgery, Washington University, Saint louis, MO, United States.
L M KlesgesDivision of Public Health Sciences, Department of Surgery, Washington University, Saint louis, MO, United States.
Sickle Cell Disease Implementation Consortium
Washington University in St. Louis · USDuke University · USMount Sinai Hospital · USRTI International · USAugusta University · USMedical University of South Carolina · USSt. Jude Children's Research Hospital · USThe University of Texas Health Science Center at Houston · USUniversity of California, San Francisco · USUniversity of Illinois Chicago · US

Funding

Washington University Implementation Science Center for Cancer Control (WU-ISCCC)P50CA244431 · NCI · WASHINGTON UNIVERSITY · PI BROWNSON, ROSS C, COLDITZ, GRAHAM A. · 2019 to 2023
$8.0M
Data Coordinating Center for Sickle Cell Disease Implementation Consortium (SCDIC)U24HL133948 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI JACOBS, SARA RUBIN, KRONER, BARBARA L · 2016 to 2021
$7.3M
New York City Sickle Cell Implementation Science ConsortiumU01HL133997 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RICHARDSON, LYNNE D. · 2016 to 2021
$5.4M
The Implementation of Cognitive Screening and Educational Support to Improve Outcomes of Adolescents and Young Adults with Sickle Cell Disease: From Clinic to the Community and BackU01HL133994 · NHLBI · WASHINGTON UNIVERSITY · PI KING, ALLISON A · 2016 to 2021
$5.2M
Improving Sickle cell care in Adolescents & Adults in Chicago (ISAAC)U01HL134042 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GORDEUK, VICTOR R, HIRSCHTICK, JANA · 2016 to 2021
$5.1M
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell DiseaseU01HL134004 · NHLBI · AUGUSTA UNIVERSITY · PI GIBSON, ROBERT WILLIAM, KUTLAR, ABDULLAH · 2016 to 2021
$5.0M
Improving SCD Care using Web-based Guidelines, Nurse Care Managers and Peer Mentors in Primary Care and Emergency Departments in Central North CarolinaU01HL133964 · NHLBI · DUKE UNIVERSITY · PI SHAH, NIRMISH R, TANABE, PAULA · 2016 to 2021
$4.8M
RE-aiming at Hydroxyurea Adherence for Sickle cell with mHealth (RE-HASH)U01HL133996 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HANKINS, JANE SILVA, KLESGES, LISA M · 2016 to 2021
$4.6M
SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease CareU01HL134007 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TREADWELL, MARSHA J, VICHINSKY, ELLIOTT P · 2016 to 2021
$4.1M
Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC)U01HL133990 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FLOREZ, HERMES JOSE · 2016 to 2021
$4.1M
NCI NIH HHS P50 CA244431NHLBI NIH HHS U01 HL133964NHLBI NIH HHS U01 HL133990NHLBI NIH HHS U01 HL133994NHLBI NIH HHS U01 HL133996NHLBI NIH HHS U01 HL133997NHLBI NIH HHS U01 HL134004NHLBI NIH HHS U01 HL134007NHLBI NIH HHS U01 HL134042NHLBI NIH HHS U24 HL133948
6 · The paper itself

Abstract

Background: Sickle Cell Disease (SCD) is a progressive genetic disease that causes organ damage and reduces longevity. Hydroxyurea is an underutilized evidence-based medication that reduces complications and improves survival in SCD. In a multi-site clinical trial, part of the NIH-funded Sickle Cell Disease Implementation Consortium (SCDIC), we evaluate the implementation of a multi-level and multi-component mobile health (mHealth) patient and provider intervention to target the determinants and context of low hydroxyurea use. Given the complexity of the intervention and contextual variability in its implementation, we combined different behavioral and implementation theories, models, and frameworks to facilitate the evaluation of the intervention implementation. In this report, we describe engagement with stakeholders, planning of the implementation process, and final analytical plan to evaluate the implementation outcomes. Methods: During 19 meetings, a 16-member multidisciplinary SCDIC implementation team created, conceived, and implemented a project that utilized Intervention Mapping to guide designing an intervention and its evaluation plan. The process included five steps: (1) needs assessment of low hydroxyurea utilization, (2) conceptual framework development, (3) intervention design process, (4) selection of models and frameworks, and (5) designing evaluation of the intervention implementation. Results: Behavioral theories guided the needs assessment and the design of the multi-level mHealth intervention. In designing the evaluation approach, we combined two implementation frameworks to best account for the contextual complexity at the organizational, provider, and patient levels: (1) the Consolidated Framework for Implementation Research (CFIR) that details barriers and facilitators to implementing the mHealth intervention at multiple levels (users, organization, intervention characteristics, broader community), and (2) the Technology Acceptance Model (TAM), a conceptual model specific for explaining the intent to use new information technology (including mHealth). The Reach Effectiveness Adoption Implementation and Maintenance (RE-AIM) framework was used to measure the outcomes. Discussion: Our research project can serve as a case study of a potential approach to combining different models/frameworks to help organize and plan the evaluation of interventions to increase medication adherence. The description of our process may serve as a blueprint for future studies developing and testing new strategies to foster evidence-based treatments for individuals living with SCD.

Indexed as

adherenceframeworkshydroxycarbamideprocess development and designsickle cell anaemia (SCA)team science

Identifiers

PMID36925803
PMCPMC10012741
OpenAlexW4317629394

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read7
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.